Study identification

EU PAS number

EUPAS20169

Study ID

28096

Official title and acronym

Time to treatment intensification in patients receiving metformin+incretin-based medicines versus metformin+other hypoglicemics (Time to treatment intensification with incretins)

DARWIN EU® study

No

Study countries

Italy

Study description

Due to the progressive nature of tipe 2 diabetes, antidiabetic drugs tend to lose their efficacy over time so that treatment intensification is required. Current guidelines recommend metformin as the first choice in newly treated patients with type 2 diabetes. Among possible second-line add-on treatments, incretin-based medicines have been associated to a more durable glycemic control, although available evidence from observational studies is conflicting. The aim of this study is to the analyse routinely collected Italian admistrative data collected from different local and regional health authorities in order to compare the time to treatment intensification in patients with type 2 diabetes receiving incretin-based medicines versus other non-insulin antidiabetics as add-on therapy to metformin.

Study status

Planned
Research institutions and networks

Institutions

Contact details

Roberto Giuseppe

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Other

More details on funding

This was a spontaneous initiative of the researchers participating to the project. No fubndings were received from any external source.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable